Market news

Detailed price information for Tenax Therapeutics (TENX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.

Tenax Therapeutics, Inc. (NASDAQ:TENX) has a possible route forward for TNX-103, but the Phase 3 LEVEL trial did not establish efficacy in the overall population. The study evaluated oral levosimendan in 241 patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF. At Week 12, the adjusted improvement in six-minute walk […]

CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET. The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage. About Tenax TherapeuticsTenax Therapeutics, Inc. is a P

Tenax (TENX) Phase 3 TNX-103 missed endpoints, but subgroup data show improved walking distance in PH-HFpEF.

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112) In the same patient population, TNX-103 produced a 47% reduction in NT-proBNP (p < 0.0001) and a 4.9 mmHg reduction in RVSP (p = 0.009) compared to placebo With full statistics analysis now complete, Company confirms TNX-103’s biological effects include marked reductions in pulmonary artery pressure and NT-proBNP, a biomarker reflecti

Detailed price information for Imunon Inc (IMNN-Q) from The Globe and Mail including charting and trades.

Tenax Therapeutics (TENX) has an average rating of buy and mean price target of $14.78, according to

Tenax Therapeutics announced Phase 3 LEVEL trial results for TNX-103, missing primary endpoints while showing subgroup benefits.

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint Orion Corporation’s license partner Tenax Therapeutics, Inc., today announced that the Phase 3 LEVEL clinical trial evaluating oral levosimendan in patients with pulmonary hypertension due to heart

TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo In prespecified exploratory...

Aug 10 () - Tenax Therapeutics said on Monday ‌its experimental heart ‌drug failed to meet the ​main goal of a late-stage study. Shares of the company plunged more than ‌80% in ⁠premarket trading following the update.

Tenax Therapeutics (NASDAQ:TENX) reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemody

Detailed price information for Tenax Therapeutics (TENX-Q) from The Globe and Mail including charting and trades.

Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended June 30, 2026 and provided an update on its corporate progress. “We are approaching an exciting moment, one for which we have been preparing since we began developing a therapy uniquely suited for PH-HFpEF. As we

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Tenax Therapeutics (TENX) has an average rating of buy and mean price target of $35.22, according to

The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Detailed price information for Allogene Therapeutics Inc (ALLO-Q) from The Globe and Mail including charting and trades.

Tipranks Press Release.